Plato Investment Management Ltd Has $932,000 Stock Position in Insulet Co. (NASDAQ:PODD)

Plato Investment Management Ltd reduced its stake in shares of Insulet Co. (NASDAQ:PODD) by 23.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,619 shares of the medical instruments supplier’s stock after selling 1,441 shares during the quarter. Plato Investment Management Ltd’s holdings in Insulet were worth $932,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. WINTON GROUP Ltd raised its position in shares of Insulet by 72.7% during the second quarter. WINTON GROUP Ltd now owns 4,534 shares of the medical instruments supplier’s stock valued at $915,000 after buying an additional 1,908 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Insulet by 4.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 87,718 shares of the medical instruments supplier’s stock worth $17,702,000 after acquiring an additional 4,065 shares during the period. Oppenheimer Asset Management Inc. lifted its position in shares of Insulet by 16.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 20,622 shares of the medical instruments supplier’s stock worth $4,162,000 after acquiring an additional 2,943 shares during the period. Thoroughbred Financial Services LLC acquired a new stake in shares of Insulet during the 2nd quarter worth approximately $407,000. Finally, Scholtz & Company LLC bought a new stake in shares of Insulet during the second quarter valued at approximately $1,847,000.

Insulet Stock Up 1.5 %

NASDAQ PODD opened at $233.87 on Monday. The stock has a market capitalization of $16.38 billion, a P/E ratio of 70.87, a price-to-earnings-growth ratio of 4.26 and a beta of 1.21. Insulet Co. has a 52 week low of $125.82 and a 52 week high of $234.71. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. The stock has a fifty day moving average of $199.23 and a 200-day moving average of $186.02.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The firm had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. During the same quarter in the previous year, the business earned $0.38 earnings per share. Insulet’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, equities research analysts forecast that Insulet Co. will post 3.04 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on PODD. UBS Group lifted their price target on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Redburn Atlantic started coverage on shares of Insulet in a research note on Thursday, May 30th. They issued a “buy” rating and a $235.00 target price on the stock. BTIG Research cut their price target on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. OTR Global reiterated a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $234.00 target price on shares of Insulet in a research report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $225.29.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.